Core Insights - Cocrystal Pharma has received approval from the Institutional Review Board at Emory University to initiate a Phase 1b human challenge study for CDI-988, aimed at preventing and treating norovirus infections [1][4] - CDI-988 is the first oral antiviral drug candidate specifically designed to target norovirus, including strains GII.4 and GII.17 [2] - The Phase 1b study will involve up to 40 healthy subjects and will assess the efficacy, safety, and pharmacokinetics of CDI-988 [3] Company Developments - The study's primary endpoint is to evaluate the reduction in clinical symptoms, while secondary endpoints include viral shedding and disease severity [3] - Cocrystal's President highlighted the significance of this study in addressing the global burden of norovirus, which causes approximately 700 million cases annually [5] - CDI-988 has shown favorable safety and tolerability data in previous Phase 1 trials, with the highest dose being 1200 mg [6] Industry Context - Norovirus is a highly contagious virus responsible for around 200,000 deaths globally each year, with significant economic impacts estimated at $60 billion [7] - In the U.S., norovirus leads to about 21 million cases of acute gastroenteritis annually, resulting in substantial healthcare costs [7] - There are currently no approved treatments or vaccines for norovirus, highlighting the potential market opportunity for CDI-988 [9]

As filed with the Securities and Exchange Commission on September 19, 2025 Registration No. 333-_______ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Cocrystal Pharma, Inc. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 35-2528215 (I.R.S. Employer Identification Number) Approxim ...

Core Insights - Assembly Biosciences, Inc. is progressing well with its antiviral portfolio, expecting key clinical data sets in 2025, including interim Phase 1b data for ABI-5366 and ABI-1179 in fall 2025 [2][3] Financial Results - As of March 31, 2025, the company reported cash, cash equivalents, and marketable securities totaling $91.0 million, down from $112.1 million as of December 31, 2024, with projections to fund operations into mid-2026 [12] - Revenue from collaborative research with Gilead was $9.4 million for Q1 2025, an increase from $5.8 million in Q1 2024, attributed to increased research and development spending and collaboration funding [12] - Research and development expenses rose to $14.9 million in Q1 2025 from $11.9 million in Q1 2024, primarily due to increased spending on ABI-6250 and ABI-5366 [12] - General and administrative expenses slightly decreased to $4.5 million in Q1 2025 from $4.6 million in Q1 2024 [12] - The net loss attributable to common stockholders was $8.8 million, or $1.17 per share, for Q1 2025, compared to a net loss of $9.1 million, or $1.66 per share, for the same period in 2024 [12] Clinical Development Updates - Ongoing clinical studies for four candidates are on track, with data expected in 2025, including interim Phase 1b data for ABI-5366 and ABI-1179 anticipated in fall 2025 [1][4] - The company plans to run concurrent studies for ABI-5366 and ABI-1179, evaluating weekly and monthly oral dosing in participants with recurrent genital herpes over a 28-day period [8] - In Q3 2025, data from a Phase 1a study in healthy participants for ABI-6250 will be assessed for safety and pharmacokinetic measures [8] - Efficacy, safety, and pharmacokinetic data from a Phase 1b study for ABI-4334 in chronic HBV infection is expected in the first half of 2025 [8] Upcoming Conferences - Assembly Biosciences presented multiple abstracts at various conferences, including ICAR, ESCMID, and EASL in 2025, showcasing data on its antiviral candidates [8]